Please login to the form below

Relvar

This page shows the latest Relvar news and features for those working in and with pharma, biotech and healthcare.

GSK gets maintenance indication for Trelegy

GSK claims Trelegy has made the strongest start of any of GSK’s new Ellipta range of respiratory meds, which also includes Relvar/Breo (fluticasone furoate/vilanterol) and Anoro (vilanterol/umeclidinium

Latest news

EMA approves GSK’s triple COPD therapy

GSK has been bringing other new COPD therapies to market - including Advair successor Breo/Relvar (fluticasone furoate and vilanterol) and Anoro (umeclidinium bromide and vilanterol) - but with greater competition in the
GSK's Witty ends on a high, but warns 2017 looking 'uncertain'

At the moment, new respiratory products such as Relvar/Breo (fluticasone furoate/vilanterol) are covering the decline in Advair, which fell 20% to £975m ($1.2bn) in the fourth quarter of
GSK files first application for triple COPD therapy

protect its franchise with the launch of new two-drug combinations such as Relvar/Breo (vilanterol/fluticasone furoate) and Anoro (vilanterol/umeclidinium bromide).
New drugs breathe life into GSK's respiratory business

New asthma and COPD drugs such as Relvar/Breo (vilanterol/fluticasone furoate) and Anoro (vilanterol/umeclidinium bromide) added £243m ($319m) in the quarter, more than offsetting a 13% decline in Seretide
GSK's triple COPD therapy tops Symbicort in phase III trial

These include GSK's Relvar/Breo (vilanterol/fluticasone furoate) and Anoro (vilanterol/umeclidinium bromide), as well as Novartis' Ultibro (glycopyrronium/indacaterol), AZ's own Duaklir (aclidinium bromide/formoterol fumarate) and Boehringer

More from news
Approximately 3 fully matching, plus 25 partially matching documents found.

Latest Intelligence

Lonely planet: why there is dwindling value in pharma travelling alone

An example is the real-world observational study GSK conducted for its respiratory treatment Relvar prior to regulatory approval.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Editorial/ Medical Director – Med Ed & Comms – Home-based...: Salary TBC

Editor – Medical Education Agency – Bucks: Salary TBC

Project Manager - Digital Healthcare - London: Excellent Remuneration Package

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Account Director, Healthcare Marketing Agency: Salary TBC

Senior Account Director/ Associate Director- Pharma and Life Sci...: Competitive salary and benefits

Editorial / Copy Lead – Healthcare Advertising – Central London...: Salary TBC

Senior Medical Writer: Competitive salary and benefits

Project Manager - Medical Communications – South Wales: Excellent Remuneration Package

Senior Account Manager- Pharma and Life Scienes: Competitive salary and benefits

Account Manager / Senior Account Manager - Healthcare Advertisin...: Excellent Remuneration

Account Director, Medical Education: Salary TBC

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Senior / Principal Medical Writer - MedComms - Home Based / Vari...: Excellent Remuneration Packages

Hybrid Role - Principal Medical Writer / Account Handler - Publi...: Salary TBC

Freelance Medical Writer - Healthcare Advertising - London: Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day

Senior Medical Writer: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Director – Healthcare PR: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Experienced / Senior Account Director - Publications - London: Up to £80, 000 plus great benefits

Home-based Principal Medical Writer – Medical Comms: Salary TBC

PR Associate Director – Consumer Health & Beauty: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality: How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA: Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad: Six behaviours separate the good brand teams from the bad...